GENET archive


1-Hormones: Indian rBGH Application WITHDRAWN!

mailinglist genet-news
-------------------------- GENET-news ---------------------------

TITLE:  Indian rBGH Application WITHDRAWN!
SOURCE: PAN AP GE Campaign Update
DATE:   July 23, 1999

----------------- archive: ------------------

Indian rBGH Application WITHDRAWN!

On July 5, 1999, PAN AP received a congratulatory message from
Devinder Sharma, co- ordinator of the Forum on Biotechnology and
Food Security (FBFS). "Following our efforts, the Indian company
(trying to import rBGH into India) has WITHDRAWN its application
for the import of rBGH!"

Previously, on June 22, he had also written, "Thanks to your
alert, we launched a strong campaign". PAN AP and FBFS had
collaborated to bring concerns over the genetically engineered
drug to the attention of the Indian government - as a result the
Indian company, Amul Research and Development Association (based
in the state of Gujerat) had been asked, at that time, to stop
the imports.

rBGH in India?

It was during the activities surrounding PAN AP 's Campaign to
deter the possible registration of rBGH in New Zealand that we
came across information that "Monsanto's recombinant bovine
growth hormone (Posilac) to increase milk production in cows and
buffaloes will be marketed by EliLilly-Ranbaxy." (Sourced from
the Listserver of D. P. S. Verma Ph.D).

PAN AP immediately dispatched an alert to partner groups in
India. We had strongly urged partners to investigate this matter
and take action on the fact that it is to be used on cows and
buffalos in India.

Forum on Biotechnology and Food Security Takes Action

Extremely concerned about this issue, the Forum on Biotechnology
and Food Security (FBFS) decided to undertake a Campaign against
the possibility of rBGH use in India. In his communications to
PAN AP, FBFS Co-ordinator, Devinder Sharma, thanked PAN AP for
the alert, which he described as "timely". He stated that he had
been in touch with top government officials, and was told that
they had approved field trials of rBGH and allowed for the import
of a certain quantity of hormonal drug. Sharma had confronted
them with the fact that Canada had only recently come out with
the startling information that rBGH can cause breast and
prostrate cancer. Concerned about this, officials had requested
further information on the Canadian situation.

In response to his request for specific information on the human
health implications of rBGH (breast cancer etc), PAN AP sent
copies of the letters of concern from Dr. Mae-wan Ho (of the Open
University), written to the New Zealand Ministry of Food and
Fibre; and Paris based ECOROPA - which detailed European
concerns, and the possible continuation of a ban on rBGH in that
region. PAN AP also sent information from the Consumer Policy
Inst. of New York - who had undertaken extensive research and
given testimonials on the problems with this drug.

With further investigation, FBFS uncovered that the drug was to
be imported from Korea. Currently, PAN AP and FBFS are
investigating the Korean link in the global rBGH spread, with the
help of select interested partners.

The New Zealand rBGH Campaign

During the months of April and May of this year, PAN AP had been
engaged in a Campaign to deter the registration of the
genetically engineered Bovine Growth Hormone (rBGH - also known
as rBST) for use in New Zealand. (See PAN AP website: for more information).

Best Wishes,
Jennifer Mourin,

PAN AP GE Campaign Coordinator

PAN Asia Pacific
P.O. Box 1170
10850 Penang Malaysia
Tel.: 604-6570271
Fax.: 604-6577445

-| Hartmut Meyer
-| Co-ordinator
-| The European NGO Network on Genetic Engineering
-| Reinhaeuser Landstr. 51
-| D - 37083 Goettingen
-| Germany
-| phone: #49-551-7700027
-| fax  : #49-551-7701672
-| email:

Genet News